These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38295186)

  • 21. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions.
    Aziz RK; Hegazy SM; Yasser R; Rizkallah MR; ElRakaiby MT
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1043-1055. PubMed ID: 30269615
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-gut microbiota interactions: implications for neuropharmacology.
    Walsh J; Griffin BT; Clarke G; Hyland NP
    Br J Pharmacol; 2018 Dec; 175(24):4415-4429. PubMed ID: 29782640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs?
    Chen F; Wen Q; Jiang J; Li HL; Tan YF; Li YH; Zeng NK
    J Ethnopharmacol; 2016 Feb; 179():253-64. PubMed ID: 26723469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut microbiome in multiple sclerosis: The players involved and the roles they play.
    Shahi SK; Freedman SN; Mangalam AK
    Gut Microbes; 2017 Nov; 8(6):607-615. PubMed ID: 28696139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of Gut Microbiota on Drug Metabolism and Guidance for Rational Drug Use Under Hypoxic Conditions at High Altitudes.
    Zhang J; Zhang J; Wang R; Jia Z
    Curr Drug Metab; 2019; 20(2):155-165. PubMed ID: 30338735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Self-emulsifying drug delivery systems (SEDDS) disrupt the gut microbiota and trigger an intestinal inflammatory response in rats.
    Subramaniam S; Elz A; Wignall A; Kamath S; Ariaee A; Hunter A; Newblack T; Wardill HR; Prestidge CA; Joyce P
    Int J Pharm; 2023 Dec; 648():123614. PubMed ID: 37979632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of the gut microbiome in cardiovascular drug response: The potential for clinical application.
    Steiner HE; Gee K; Giles J; Knight H; Hurwitz BL; Karnes JH
    Pharmacotherapy; 2022 Feb; 42(2):165-176. PubMed ID: 34820870
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dissecting the human gut microbiome to better decipher drug liability: A once-forgotten organ takes center stage.
    Cai J; Auster A; Cho S; Lai Z
    J Adv Res; 2023 Oct; 52():171-201. PubMed ID: 37419381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Microbiota and Gut-Related Disorders: Insights from Animal Models.
    Kamareddine L; Najjar H; Sohail MU; Abdulkader H; Al-Asmakh M
    Cells; 2020 Nov; 9(11):. PubMed ID: 33147801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs and gut microbiome interactions-an emerging field of tailored medicine.
    Khan I
    BMC Pharmacol Toxicol; 2023 Aug; 24(1):43. PubMed ID: 37649091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Connecting the dots: Targeting the microbiome in drug toxicity.
    Luo Y; Zhou T
    Med Res Rev; 2022 Jan; 42(1):83-111. PubMed ID: 33856076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exploring the Involvement of Gut Microbiota in Cancer Therapy-Induced Cardiotoxicity.
    Kunika ; Frey N; Rangrez AY
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility.
    Ozdal T; Sela DA; Xiao J; Boyacioglu D; Chen F; Capanoglu E
    Nutrients; 2016 Feb; 8(2):78. PubMed ID: 26861391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of the gut microbiome on toxigenic bacteria.
    Koosha RZ; Fazel P; Sedighian H; Behzadi E; Ch MH; Imani Fooladi AA
    Microb Pathog; 2021 Nov; 160():105188. PubMed ID: 34530074
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential Implications of Gut Microbiota in Drug Pharmacokinetics and Bioavailability.
    Flowers SA; Bhat S; Lee JC
    Pharmacotherapy; 2020 Jul; 40(7):704-712. PubMed ID: 32463481
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis.
    Fan J; Jiang T; He D
    Front Immunol; 2023; 14():1189036. PubMed ID: 37841256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Microbiome and Its Potential for Pharmacology.
    Chavira A; Belda-Ferre P; Kosciolek T; Ali F; Dorrestein PC; Knight R
    Handb Exp Pharmacol; 2019; 260():301-326. PubMed ID: 31820171
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Microbiota-Host Transgenomic Metabolism, Bioactive Molecules from the Inside.
    Turroni S; Brigidi P; Cavalli A; Candela M
    J Med Chem; 2018 Jan; 61(1):47-61. PubMed ID: 28745893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug Metabolism by the Host and Gut Microbiota: A Partnership or Rivalry?
    Swanson HI
    Drug Metab Dispos; 2015 Oct; 43(10):1499-504. PubMed ID: 26261284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The gut microbiome influences the bioavailability of olanzapine in rats.
    Cussotto S; Walsh J; Golubeva AV; Zhdanov AV; Strain CR; Fouhy F; Stanton C; Dinan TG; Hyland NP; Clarke G; Cryan JF; Griffin BT
    EBioMedicine; 2021 Apr; 66():103307. PubMed ID: 33819741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.